Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.63 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 10/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14282787 | 0.87 | NR1H4 (0.68) | NR1H4GRM5 | |
| SCHEMBL8274858 | 0.87 | NR1H4 (0.68) | NR1H4GRM5 | |
| Hydrochloric Acid SCHEMBL4955440 | 0.86 | NR1H4 (0.67) | NR1H4GRM5 | |
| Hydrochloric Acid SCHEMBL4955448 | 0.86 | NR1H4 (0.67) | NR1H4GRM5 | |
| Hydrochloric Acid SCHEMBL4956975 | 0.86 | NR1H4 (0.67) | NR1H4GRM5 | |
| SCHEMBL14153063 | 0.84 | NR1H4 (0.64) | NR1H4GRM5 | |
| SCHEMBL8274898 | 0.80 | NR1H4 (0.74) | NR1H4BCHEACHE | |
| SCHEMBL8276225 | 0.80 | NR1H4 (0.74) | NR1H4BCHEACHE | |
| SCHEMBL15848298 | 0.80 | NR1H4 (0.74) | NR1H4BCHEACHE | |
| Hydrochloric Acid SCHEMBL4786805 | 0.79 | NR1H4 (0.72) | NR1H4BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| WO-2005121131-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015146-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP3 | NR1H4 1322/4885BCHE 258/4885ACHE 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.